Alexza Announces Submission Of AZ-004 (Staccato(R) Loxapine) NDA

Links shared publicly online about this topic.

  • 1,527
    total visits

Alexza Announces Submission Of AZ-004 (Staccato(R) Loxapine) NDA

medicalnewstoday.com —

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has submitted its New Drug Application (NDA) for Staccato® loxapine (AZ-004) to the US Food and Drug Administration (FDA). AZ-004

View full resource at medicalnewstoday.com

Tags: Drug, Pharma, FDA

  • Share

Most Recently Shared on December 16, 2009 at 11:17 am By:

mnt_clinical MNT Clinical Trials

Alexza Announces Submission Of AZ-004 (Staccato(R) Loxapine) NDA http://mnt.to/3vxf

2 years ago...

Reply

Retweet

Favorite

Advertisement